Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Acute Care for Patients Who Are Incarcerated: A Review.

Haber LA, Erickson HP, Ranji SR, Ortiz GM, Pratt LA.

JAMA Intern Med. 2019 Sep 16. doi: 10.1001/jamainternmed.2019.3881. [Epub ahead of print]

PMID:
31524937
2.

By the Light of Day: Quality, Safety, and Education During the Overnight Admission Handoff.

Devendra GP, Ortiz GM, Haber LA.

Cureus. 2019 Apr 23;11(4):e4529. doi: 10.7759/cureus.4529.

3.

Acute Clinical Care for Transgender Patients: A Review.

Rosendale N, Goldman S, Ortiz GM, Haber LA.

JAMA Intern Med. 2018 Nov 1;178(11):1535-1543. doi: 10.1001/jamainternmed.2018.4179. Review.

PMID:
30178031
4.

Unusual Radiographic Presentation of Pneumocystis Pneumonia in a Patient with AIDS.

Block BL, Mehta T, Ortiz GM, Ferris SP, Vu TH, Huang L, Cattamanchi A.

Case Rep Infect Dis. 2017;2017:3183525. doi: 10.1155/2017/3183525. Epub 2017 Dec 7.

5.

Clearing the air: inpatient providers' knowledge, perspectives, and experience with electronic cigarettes.

Haber LA, Ortiz GM.

J Hosp Med. 2014 Dec;9(12):805-7. doi: 10.1002/jhm.2279. Epub 2014 Oct 29. No abstract available.

PMID:
25352497
6.

Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4(+) T cell recovery after the initiation of antiretroviral therapy for HIV disease.

Seu L, Ortiz GM, Burt TD, Deeks SG, Martin JN, McCune JM.

AIDS Res Ther. 2014 Aug 5;11:27. doi: 10.1186/1742-6405-11-27. eCollection 2014.

7.

Higher CD27+CD8+ T cells percentages during suppressive antiretroviral therapy predict greater subsequent CD4+ T cell recovery in treated HIV infection.

Seu L, Ortiz GM, Epling L, Sinclair E, Swainson LA, Bajpai UD, Huang Y, Deeks SG, Hunt PW, Martin JN, McCune JM.

PLoS One. 2013 Dec 31;8(12):e84091. doi: 10.1371/journal.pone.0084091. eCollection 2013.

8.

Morphine produces immunosuppressive effects in nonhuman primates at the proteomic and cellular levels.

Brown JN, Ortiz GM, Angel TE, Jacobs JM, Gritsenko M, Chan EY, Purdy DE, Murnane RD, Larsen K, Palermo RE, Shukla AK, Clauss TR, Katze MG, McCune JM, Smith RD.

Mol Cell Proteomics. 2012 Sep;11(9):605-18. doi: 10.1074/mcp.M111.016121. Epub 2012 May 11.

9.

Development and validation of a method for allantoin determination in liposomes and pharmaceutical formulations.

Braga RR, Sales J, Marins Rde C, Ortiz GM, Garcia S.

Spectrochim Acta A Mol Biomol Spectrosc. 2012 Jun;91:389-94. doi: 10.1016/j.saa.2012.02.022. Epub 2012 Feb 14.

PMID:
22391226
10.

An assessment of continued use and health impact of the concrete biosand filter in Bonao, Dominican Republic.

Aiken BA, Stauber CE, Ortiz GM, Sobsey MD.

Am J Trop Med Hyg. 2011 Aug;85(2):309-17. doi: 10.4269/ajtmh.2011.09-0122.

11.

A randomized controlled trial of the concrete biosand filter and its impact on diarrheal disease in Bonao, Dominican Republic.

Stauber CE, Ortiz GM, Loomis DP, Sobsey MD.

Am J Trop Med Hyg. 2009 Feb;80(2):286-93. Erratum in: Am J Trop Med Hyg. 2009 Apr;80(4):686.

PMID:
19190228
12.

Characterisation of the biosand filter for E. coli reductions from household drinking water under controlled laboratory and field use conditions.

Stauber CE, Elliott MA, Koksal F, Ortiz GM, DiGiano FA, Sobsey MD.

Water Sci Technol. 2006;54(3):1-7.

PMID:
17037125
13.

Detection of T lymphocytes specific for human endogenous retrovirus K (HERV-K) in patients with seminoma.

Rakoff-Nahoum S, Kuebler PJ, Heymann JJ, E Sheehy M, Ortiz GM, S Ogg G, Barbour JD, Lenz J, Steinfeld AD, Nixon DF.

AIDS Res Hum Retroviruses. 2006 Jan;22(1):52-6.

PMID:
16438646
14.

Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3.

Plana M, Garcia F, Oxenius A, Ortiz GM, Lopez A, Cruceta A, Mestre G, Fumero E, Fagard C, Sambeat MA, Segura F, Miró JM, Arnedo M, Lopalcos L, Pumarola T, Hirschel B, Phillips RE, Nixon DF, Gallart T, Gatell JM.

J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):791-9.

PMID:
15213562
15.

Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection.

Alexander TH, Ortiz GM, Wellons MF, Allen A, Grace EJ 2nd, Schweighardt B, Brancato J, Sandberg JK, Furlan SN, Miralles GD, Nixon DF, Bartlett JA.

J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):475-81.

PMID:
14657757
16.

Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene.

Karlsson AC, Deeks SG, Barbour JD, Heiken BD, Younger SR, Hoh R, Lane M, Sällberg M, Ortiz GM, Demarest JF, Liegler T, Grant RM, Martin JN, Nixon DF.

J Virol. 2003 Jun;77(12):6743-52.

17.

A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study.

García F, Plana M, Arnedo M, Ortiz GM, Miró JM, Lopalco L, Lori F, Pumarola T, Gallart T, Gatell JM.

AIDS. 2003 Jan 3;17(1):43-51.

PMID:
12478068
18.

Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions.

Schweighardt B, Ortiz GM, Grant RM, Wellons M, Miralles GD, Kostrikis LG, Bartlett JA, Nixon DF.

AIDS. 2002 Nov 22;16(17):2342-4.

PMID:
12441810
19.

Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection.

Ortiz GM, Hu J, Goldwitz JA, Chandwani R, Larsson M, Bhardwaj N, Bonhoeffer S, Ramratnam B, Zhang L, Markowitz MM, Nixon DF.

J Virol. 2002 Jan;76(1):411-5.

20.

Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.

Ortiz GM, Wellons M, Brancato J, Vo HT, Zinn RL, Clarkson DE, Van Loon K, Bonhoeffer S, Miralles GD, Montefiori D, Bartlett JA, Nixon DF.

Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13288-93. Epub 2001 Oct 30.

21.

The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection.

García F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, Vidal C, Cruceta A, Arnedo M, Gil C, Pantaleo G, Pumarola T, Gallart T, Nixon DF, Miró JM, Gatell JM.

AIDS. 2001 Jun 15;15(9):F29-40.

PMID:
11416735
22.

Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection.

Bonhoeffer S, Rembiszewski M, Ortiz GM, Nixon DF.

AIDS. 2000 Oct 20;14(15):2313-22.

PMID:
11089619
23.

Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption.

Papasavvas E, Ortiz GM, Gross R, Sun J, Moore EC, Heymann JJ, Moonis M, Sandberg JK, Drohan LA, Gallagher B, Shull J, Nixon DF, Kostman JR, Montaner LJ.

J Infect Dis. 2000 Sep;182(3):766-75. Epub 2000 Aug 17.

PMID:
10950770
24.

The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy.

Binley JM, Schiller DS, Ortiz GM, Hurley A, Nixon DF, Markowitz MM, Moore JP.

J Infect Dis. 2000 Apr;181(4):1249-63. Epub 2000 Apr 13.

PMID:
10762561
25.

HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.

Ortiz GM, Nixon DF, Trkola A, Binley J, Jin X, Bonhoeffer S, Kuebler PJ, Donahoe SM, Demoitie MA, Kakimoto WM, Ketas T, Clas B, Heymann JJ, Zhang L, Cao Y, Hurley A, Moore JP, Ho DD, Markowitz M.

J Clin Invest. 1999 Sep;104(6):R13-8.

26.

Palatal changes associated with reverse smoking in Filipino women.

Ortiz GM, Pierce AM, Wilson DF.

Oral Dis. 1996 Sep;2(3):232-7.

PMID:
9081765

Supplemental Content

Loading ...
Support Center